Related Experiment Video
Updated: Oct 4, 2025
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
Published on: October 4, 2022
RhoGDI2 induced malignant phenotypes of pancreatic cancer cells via regulating Snail expression
Bin Yi1, You Hu1, Dongming Zhu1
1Department of General Surgery, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, People's Republic of China.
Background:
Rho GDP dissociation inhibitor 2 (RhoGDI2) has been shown to contribute to the aggressive phenotypes of human cancers, such as tumor metastasis and chemoresistance.
Objective:
This study aimed to assess the effects of RhoGDI2 on tumor progression and chemoresistance in pancreatic cancer cells.
Methods:
The expression of RhoGDI2 in pancreatic cancer cells was detected by Western blot analysis. Gain-of-function and loss-of-function approaches were done to examine the malignant phenotypes of the RhoGDI2-expressing or RhoGDI2-depleting cells. The correlation between RhoGDI2 and Snail was also analyzed.
Results:
Differential expression of RhoGDI2 protein in pancreatic cancer cell lines was identified. Gain-of-function and loss-of-function experiments showed that RhoGDI2 induced the malignant phenotypes of pancreatic cancer cells, including proliferation, migration, invasion, and gemcitabine (GEM) chemoresistance. The upregulation of RhoGDI2 stimulated the expression of Snail, resulting in the altered expression of epithelial marker E-cadherin and mesenchymal marker Vimentin, which were characteristics of the tumorigenic activity of epithelial-mesenchymal transition. The expression of RhoGDI2 and Snail was upregulated in clinical tumor samples, and higher expression of RhoGDI2 or Snail was significantly associated with poor patient survival in pancreatic ductal adenocarcinoma (PDAC).
Conclusion:
The findings indicated that RhoGDI2 promoted GEM resistance and tumor progression in pancreatic cancer and that RhoGDI2 might be a potential therapeutic target in patients with PDAC.
Insights
Rho GDP dissociation inhibitor 2 (RhoGDI2) promotes pancreatic cancer progression and gemcitabine resistance by upregulating Snail and driving epithelial-mesenchymal transition. Targeting RhoGDI2 may offer a therapeutic strategy for pancreatic ductal adenocarcinoma (PDAC) patients.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Rho GDP dissociation inhibitor 2 (RhoGDI2) is implicated in aggressive cancer phenotypes, including metastasis and chemoresistance.
- Understanding RhoGDI2's role in pancreatic cancer is crucial due to the disease's aggressive nature and limited treatment options.
Purpose of the Study:
- To investigate the impact of RhoGDI2 on tumor progression and chemoresistance in pancreatic cancer.
- To explore the relationship between RhoGDI2, Snail, and epithelial-mesenchymal transition (EMT) markers in pancreatic cancer.
Main Methods:
- Western blot analysis to detect RhoGDI2 expression in pancreatic cancer cell lines.
- Gain-of-function and loss-of-function studies to assess RhoGDI2's effects on cellular phenotypes.
- Analysis of the correlation between RhoGDI2, Snail, E-cadherin, and Vimentin expression.
Main Results:
- RhoGDI2 expression was differentially detected in pancreatic cancer cell lines.
- RhoGDI2 overexpression enhanced proliferation, migration, invasion, and gemcitabine (GEM) resistance.
- RhoGDI2 upregulated Snail, leading to altered E-cadherin and Vimentin expression, indicative of EMT.
- Elevated RhoGDI2 and Snail levels in clinical samples correlated with poor patient survival in pancreatic ductal adenocarcinoma (PDAC).
Conclusions:
- RhoGDI2 significantly promotes tumor progression and gemcitabine resistance in pancreatic cancer.
- RhoGDI2 is a potential therapeutic target for patients with pancreatic ductal adenocarcinoma (PDAC).
Related Concept Videos
02:33Hedgehog Signaling Pathway
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...